SynthesisBMC ophthalmology2020
Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis.
Synthesis in BMC ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 5 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Dose-Dependent Effects of Atropine on Accommodative and Binocular Visual Function for Myopia Control in Children: A Systematic Review and Meta-Analysis.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Pooled it
- Benefits and risks of orthokeratology treatment: a systematic review and meta-analysis.International ophthalmology · 2024Pooled it
- Pooled it
- Effects of atropine on choroidal thickness in myopic children: a meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Varying Dose of Atropine in Slowing Myopia Progression in Children Over Different Follow-Up Periods by Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Comparison of the influence of 1% and 0.01% atropine on the corneal topography in myopic children.BMC ophthalmology · 2025Trial
- Identifying potential therapeutic targets for high myopia via a case-control study and Mendelian randomisation analyses of the human blood metabolome.Eye (London, England) · 2026Article
- Comparative efficacy of twice-daily 0.01% atropine combined with Orthokeratology versus DIMS lenses in myopia control: an elastic net penalized regression analysis.BMC ophthalmology · 2026Article
- Low-Concentration Atropine (0.01%, 0.025%, 0.05%) for Myopia Progression in Children: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Efficacy of Tuina for Myopia in Children: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2026Article
- Atropine Eye Drops in Childhood Myopia Control: A Review.International journal of medical sciences · 2026Review
- Multifocal electroretinography assessment of retinal responses to myopic defocus lenses.PeerJ · 2026Article
- Resolution of Near-Work-Related Effects, Accommodation, and Binocular Vision Changes of 0.05% Atropine After 1 Year: Secondary Analysis of a Prospective Study.Ophthalmology and therapy · 2025Article
- Article
- Comparison of two main orthokeratology lens designs in effectiveness and safety for myopia control in different ages.Frontiers in medicine · 2025Article
- The role of atropine in myopia control: insights into choroidal and scleral mechanisms.Frontiers in pharmacology · 2025Article
- Pharmaceutical Prescribing Privileges for Optometrists to Combat Childhood Myopia in Singapore: Public Health Policy Review and Analysis.Children (Basel, Switzerland) · 2024Review
- The Effect of Alternating Monocular Instillation of 0.125% Atropine in Korean Children with Progressive Myopia.Journal of clinical medicine · 2024Article
- Comparison of the long-term effects of atropine in combination with Orthokeratology and defocus incorporated multiple segment lenses for myopia control in Chinese children and adolescents.Eye (London, England) · 2024Article
- Low concentration atropine and myopia: a narrative review of the evidence for United Kingdom based practitioners.Eye (London, England) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effect and safety of atropine on delaying the progression of myopia has been extensively studied, but its optimal dose is still unclear. Therefore, the purpose of this meta-analysis is to systematically evaluate the safety and effectiveness of atropine in controlling the progression of myopia, and to explore the relationship between the dose of atropine and the effectiveness of controlling the progression of myopia.
methodsThis work was done through the data searched from PubMed, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. The Cochrane Handbook was also used to evaluate the quality of the included studies. In addition, a meta-analysis was performed using Revman5.3 software.
resultsA total of 10 randomized controlled trials (RCTs) were included. Myopia progression was mitigated greater in the atropine treatment group than that in the control group, with MD = - 0.80, 95% CI (- 0.94, - 0.66) during the whole observation period. There was a statistical difference among 0.05, 0.5, and 1.0% atropine (P = 0.004). In addition, less axial elongation was shown, with MD = - 0.26, 95% CI (- 0.33, - 0.18) during the whole observation period.
conclusionThe effectiveness of atropine in controlling the progression of myopia was dose related. A 0.05% atropine was likely to be the optimal dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.